专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2929354A1 BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 失效
标题翻译：生物标记ZUR AUSWAHL EINER THERAPIE VON HERZVERSAGEN
公开(公告)号：EP2929354A1
公开(公告)日：2015-10-14
申请号：EP13799310.1
申请日：2013-12-04
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4745 , G01N2333/475 , G01N2333/705 , G01N2800/325 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.
摘要翻译：本发明涉及一种用于鉴定适合于施用选自β-阻断剂，醛固酮拮抗剂，利尿剂和肾素 - 血管紧张素系统的抑制剂的至少一种药物的受试者的方法。该方法基于选自GDF-15（生长分化因子15），内皮抑制素，拟米卡因，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，BNP-15的至少一种生物标志物的量的测定。来自患有心力衰竭的受试者的样品中的类型肽，尿酸，Gal3（Galectin-3），骨桥蛋白，sST2（可溶性ST2），PlGF，sFlt-1，P1NP，半胱氨酸蛋白酶抑制剂C，前白蛋白和转铁蛋白。此外，该方法包括将所确定的量与参考量进行比较的步骤。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。本发明还涉及用于鉴定适合于给予本文公开的至少一种药物的受试者的系统以及用于执行本文所公开的方法的试剂和试剂盒。

2. 发明申请

WO2014086833A1 BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 审中-公开
标题翻译：生物标志物选择心脏失败的治疗方法
公开(公告)号：WO2014086833A1
公开(公告)日：2014-06-12
申请号：PCT/EP2013/075491
申请日：2013-12-04
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
发明人： ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4745 , G01N2333/475 , G01N2333/705 , G01N2800/325 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, PlNP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.
摘要翻译：本发明涉及一种用于鉴定有资格给予选自β-阻滞剂，醛固酮拮抗剂，利尿剂和肾素 - 血管紧张素系统抑制剂的至少一种药物的受试者的方法。该方法基于选自GDF-15（生长分化因子15），内皮抑素，mimecan，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，BNP-15的至少一种生物标志物的量的测定。来自患有心力衰竭的受试者的样品中的类型肽，尿酸，Gal3（Galectin-3），骨桥蛋白，sST2（可溶性ST2），PlGF，sFlt-1，PlNP，半胱氨酸蛋白酶抑制剂C，前白蛋白和转铁蛋白。此外，该方法包括将所确定的量与参考量进行比较的步骤。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。本发明还涉及用于鉴定合适的给予本文公开的至少一种药物的受试者的系统以及用于执行本文所公开的方法的试剂和试剂盒。

3. 发明授权

EP2929354B1 BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 失效
标题翻译：生物标志物在选择心力衰竭治疗中的作用
公开(公告)号：EP2929354B1
公开(公告)日：2018-04-18
申请号：EP13799310.1
申请日：2013-12-04
申请人： Roche Diagnostics GmbH , F. Hoffmann-La Roche AG
发明人： ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4745 , G01N2333/8139 , G01N2800/325 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式